Literature DB >> 22198073

Differential effects of acyclic nucleoside phosphonates on nitric oxide and cytokines in rat hepatocytes and macrophages.

Petra Kostecká1, Antonín Holý, Hassan Farghali, Zdeněk Zídek, Eva Kmoníčková.   

Abstract

Acyclic nucleoside phosphonates (ANP) are virostatics effective against viruses like hepatitis B virus and human immunodeficiency virus. Our previous reports indicated immunomodulatory activities of ANP in mouse and human innate immune cells. Recently, evidence has increased that hepatocytes may play an active role in immune regulation of the liver homeostasis or injury. In this study we investigated possible immunomodulatory effects of ANP on rat hepatocytes and macrophages. Nitric oxide (NO) production and secretion of cytokines (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-13, IL-18, IFN-γ, TNF-α and GM-CSF) were analyzed under in vitro conditions. Test compounds included: 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA; adefovir); 9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP); (R)- and (S)-enantiomers of 9-[2-(phosphonomethoxy)propyl]adenine [(R)-PMPA; tenofovir] and [(S)-PMPA]; 9-[2-(phosphonomethoxy)propyl]-2,6-diaminopurine [(R)-PMPDAP] and [(S)-PMPDAP]. The group of test compounds also included their N(6)-substituted derivatives. Some of ANP which are able to induce NO production and cytokine secretion in cultured macrophages possess the same immunobiological activity in isolated hepatocytes. The extent of responses is in range of LPS/IFN-γ stimulation in both types of cells. The effects of active ANP on NO expression and cytokine secretion are dose- and time-dependent. Interestingly, the spectrum of detected cytokines induced by ANP is broader in hepatocytes. The results also confirm immunomodulatory effects of some ANP on rodent macrophages. Moreover, we demonstrate for the first time immunobiological reactivity of primary rat hepatocytes induced by exogenous ANP compounds. The potential of hepatocytes to synthesize cytokines can contribute to better understanding of liver immune function and can serve for pharmacological intervention in liver diseases.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198073     DOI: 10.1016/j.intimp.2011.12.005

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  5 in total

1.  The negative effect of magnetic nanoparticles with ascorbic acid on peritoneal macrophages.

Authors:  Klára Jiráková; Maksym Moskvin; Lucia Machová Urdzíková; Pavel Rössner; Fatima Elzeinová; Milada Chudíčková; Daniel Jirák; Natalia Ziolkowska; Daniel Horák; Šárka Kubinová; Pavla Jendelová
Journal:  Neurochem Res       Date:  2019-04-03       Impact factor: 3.996

2.  Pre-exposure prophylaxis differentially alters circulating and mucosal immune cell activation in herpes simplex virus type 2 seropositive women.

Authors:  Laura E Richert-Spuhler; Laura Pattacini; Margot Plews; Elizabeth Irungu; Timothy R Muwonge; Elly Katabira; Nelly Mugo; Adrienne F A Meyers; Connie Celum; Jared M Baeten; Jairam R Lingappa; Jennifer M Lund
Journal:  AIDS       Date:  2019-11-15       Impact factor: 4.177

3.  Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals.

Authors:  Jose R Castillo-Mancilla; Amie Meditz; Cara Wilson; Jia-Hua Zheng; Brent E Palmer; Eric J Lee; Edward M Gardner; Sharon Seifert; Becky Kerr; Lane R Bushman; Samantha MaWhinney; Peter L Anderson
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

4.  Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.

Authors:  Julia Del Amo; Rosa Polo; Santiago Moreno; Asunción Díaz; Esteban Martínez; José Ramón Arribas; Inma Jarrín; Miguel A Hernán
Journal:  Ann Intern Med       Date:  2020-06-26       Impact factor: 25.391

5.  Screening of FDA-Approved Drug Library Identifies Adefovir Dipivoxil as Highly Potent Inhibitor of T Cell Proliferation.

Authors:  Linda Voss; Karina Guttek; Annika Reddig; Annegret Reinhold; Martin Voss; Burkhart Schraven; Dirk Reinhold
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.